Marshall Wace North America’s BeOne Medicines Ltd ONC Stock Holding History

Marshall Wace North America’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,200	Closed	-$1.08M	–	1823
2020 Q4	$1.08M	Buy	+4,200	New	+$1.16M	﹤0.01%	927
2019 Q3	–	Sell	-9,718	Closed	-$1.2M	–	1588
2019 Q2	$1.2M	Buy	9,718 +9,140	+1,581%	+$1.16M	0.01%	698
2019 Q1	$76K	Buy	+578	New	+$78K	﹤0.01%	1172

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Marshall Wace North America's ONC Position: Q1 2021 in Review

Marshall Wace North America sold out of BeOne Medicines Ltd (ONC) in Q1 2021, closing a stake of 4,200 shares — an estimated $1.08M sold.

Marshall Wace North America first reported a position in ONC in Q1 2019 and held it in 3 quarters. The position peaked at $1.2M in Q2 2019. 253 funds tracked by Wall St. Rank hold ONC as of Q1 2021.

Marshall Wace North America reported no remaining BeOne Medicines Ltd position as of Q1 2021 after selling out during the quarter.
Marshall Wace North America sold 4,200 BeOne Medicines Ltd shares in Q1 2021, an estimated $1.08M.
Marshall Wace North America first reported a position in BeOne Medicines Ltd in Q1 2019 and held it in 3 quarters.
Marshall Wace North America's BeOne Medicines Ltd position peaked at $1.2M in Q2 2019.
253 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.